Taipei, Taiwan, 10 December 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for November 2025 of NT$1,059 million, flat compared to same period last year. Lotus's November 2025 year-to-date (YTD) revenue of NT$18,059 million increased by 5% YoY compared to the same period last year.
Lotus's Asia business grew 14% YoY in YTD November 2025. Growth continued to be driven by strong performance in Thailand and Vietnam, resulting in a 115% YoY increase in the Southeast Asian markets. Asia was also supported by the resilient single-digit growth in mature markets in Taiwan and Korea, despite a ~7% YoY depreciation of the KRW against NTD. Export markets slightly declined by 3% YoY compared to YTD November 2024, as the double-digit YoY growth in Lenalidomide in the US was offset by lower contributions from other export products as well as a ~3% depreciation of USD against NTD during the comparable periods.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com